Healthcare niche Leverage Leerink Partners' specialized healthcare focus and strong advisory track record (over $70B advised, $180B raised) to position as a strategic partner for mid to large cap biotech and specialty pharma clients seeking capital markets guidance and transformative transactions.

Strategic partnerships Recent client wins and leadership movements (Crinetics signing with Leerink and JPMorgan; new Senior Advisor Stephen Sands) indicate ongoing capacity to support complex deals and talent-driven engagements, presenting cross-sell opportunities for advisory, capital raising, and trading execution services.

Global healthcare events Active participation in the 2026 Global Healthcare Conference and related events signals opportunities to engage healthcare companies preparing for financings, M&A, or partnerships; target firms planning IPOs or follow-on rounds aligned with Leerink’s bookrunning capabilities.

Execution capabilities With a revenue range of $250M-$500M and a client roster that includes public offerings and private placements, there is potential to upsell enhanced execution services, cross-border advisory, and flagship capital-raising mandates to growth-stage biotech and gene therapy companies.

Regulatory & tech edge Leerink’s broker-dealer status and tech stack integrations (OneTrust, Sitelinks Search Box, LinkedIn, etc.) can be marketed to prospects seeking compliant distribution, robust digital due diligence, and efficient investor reach, enabling targeted outreach to healthcare startups accelerating to public markets.